ReviewCancer journal (Sudbury, Mass.)
Novel gamma-chain cytokines as candidate immune modulators in immune therapies for cancer.
Review in Cancer journal (Sudbury, Mass.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Beyond priming: a sequential, feedback-guided adjuvant framework for therapeutic cancer peptide vaccines in immunologically cold tumors.Frontiers in immunology · 2026Review
- Nicotine exhausts CD8Cancer immunology, immunotherapy : CII · 2021Article
- BCG vaccination induces enhanced frequencies of memory T cells and altered plasma levels of common γc cytokines in elderly individuals.PloS one · 2021Article
- IL-2 And IL-15 Induced NKG2D, CD158a and CD158b Expression on T, NKT- like and NK Cell Lymphocyte Subsets from Regional Lymph Nodes of Melanoma Patients.Pathology oncology research : POR · 2020Article
- Dietary Crocin Reverses Melanoma Metastasis.Journal of biomedical research · 2017Article
- Common gamma chain cytokines in combinatorial immune strategies against cancer.Immunology letters · 2016Review
- Starved and Asphyxiated: How Can CD8(+) T Cells within a Tumor Microenvironment Prevent Tumor Progression.Frontiers in immunology · 2016Review
- Concepts of immunotherapy for glioma.Journal of neuro-oncology · 2015Review
- Targeting T cell metabolism for therapy.Trends in immunology · 2015Review
- Antibody-cytokine fusion proteins for treatment of cancer: engineering cytokines for improved efficacy and safety.Seminars in oncology · 2014Review
- Review
- Engineered fusokine GIFT4 licenses the ability of B cells to trigger a tumoricidal T-cell response.Cancer research · 2014Article
- IL-21 promotes CD4 T cell responses by phosphatidylinositol 3-kinase-dependent upregulation of CD86 on B cells.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
- Abrogation of SRC homology region 2 domain-containing phosphatase 1 in tumor-specific T cells improves efficacy of adoptive immunotherapy by enhancing the effector function and accumulation of short-lived effector T cells in vivo.Journal of immunology (Baltimore, Md. : 1950) · 2012Article
- Characterization of recombinant human IL-15 deamidation and its practical elimination through substitution of asparagine 77.Pharmaceutical research · 2012Article
- Umbilical cord blood immunology: relevance to stem cell transplantation.Clinical reviews in allergy & immunology · 2012Review
- Interleukin-7, but not thymic stromal lymphopoietin, plays a key role in the T cell response to influenza A virus.PloS one · 2012Article
- Article
- Cancer immunotherapy comes of age.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2011Review
- Natural killer cell engineering for cellular therapy of cancer.Tissue antigens · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Cytokines that signal through the common-gamma chain are potent growth factors for T cells and natural killer cells. Interleukin (IL)-2, the gammac prototype, can mediate antitumor effects as a single agent or in the context of multimodality regimens but is limited by side effects and a propensity for expansion of regulatory T cells. IL-7, IL-15, and IL-21 each possess properties that can be exploited in the context of immunotherapy for cancer. Each has been demonstrated to mediate potent vaccine adjuvant effects in tumor models, and each can enhance the effectiveness of adoptive immunotherapies. Although the overlap among the agents is significant, IL-7 is uniquely immunorestorative and preferentially augments reactivity of naive populations, IL-15 potently augments reactivity of CD8 memory cells and natural killer cells, and IL-21 preferentially expands the inflammatory Th17 subset and may limit terminal differentiation of effector CD8 cells. Clinical trials of IL-7 and IL-21 have already been completed and, so far, demonstrate safety and biologic activity of these agents. Clinical trials of IL-15 are expected soon. Ultimately, these agents are expected to be most effective in the context of multimodal immunotherapy regimens, and careful clinical trial design will be needed to efficiently identify the proper doses, regimens, and settings in which to exploit their biologic properties for therapeutic gain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.